Paul McKenzie, PhD, is the Executive Vice President of Pharmaceutical Operations & Technology and Biosimilars at Biogen and has served on the Executive Committee since July 2016. Dr. McKenzie is responsible for asset management, technical development, global manufacturing, supply chain operations, quality, engineering and biosimilars business. He also oversees construction and operation of Biogen’s advanced biologics manufacturing facility in Solothurn, Switzerland. Dr. McKenzie serves on board of directors for Samsung Bioepis.

He joined the Company in February 2016, as Senior Vice President for Global Biologics Manufacturing & Technical Operations. Prior to joining Biogen, Dr. McKenzie was most recently Vice President of R&D for Johnson & Johnson’s Ethicon business. During his tenure at J&J, he led the manufacturing and technical operations team, responsible for internal and external manufacturing of Janssen’s pharmaceutical portfolio as well as Global Development for Janssen R&D, helping to manage pipeline activities from discovery through clinical development and commercialization. He also held various R&D and manufacturing positions at Bristol-Myers Squibb and Merck.

Dr. McKenzie holds a B.S. in Chemical Engineering from the University of Pennsylvania and a PhD in Chemical Engineering from Carnegie Mellon University. He has served on numerous professional and academic boards, most recently Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering.